
On Tuesday, private equity firm Madison Dearborn Partners said it would buy MoneyGram in a $1.8 billion deal, seeking to turn around the fortunes of the debt-laden money transfer platform buffeted by stiff competition, reported Reuters.
Funds affiliated with Madison will acquire MoneyGram for $11 per share, a 23% premium to the stock’s close on Monday. The offer is also 50% higher than the closing price of MoneyGram shares on Dec. 14, a day before media speculation on the deal.
The Dallas-based company, with nearly $800 million in net debt and more than 150 million customers, became an acquisition target as it struggled to capture the growing market for payments and remittances amid competition from rivals such as Remitly Global and Western Union.
It had engaged with potential buyers several times in the last few years, including in 2018 when its $1.2 billion sale to China’s Ant Financial fell through because of the US government’s concerns over national security.
Want more news? Subscribe to CPI’s free daily newsletter for more headlines and updates on antitrust developments around the world.
Featured News
Fortnite Returns to Apple’s U.S. App Store After Five-Year Ban
May 21, 2025 by
CPI
Federal Court to Hear Case on Trump’s Firing of FTC Democrats
May 20, 2025 by
CPI
UK Government Suffers Third Successive Defeat on Data (Use and Access) Bill
May 20, 2025 by
CPI
Sex Toy Retailer Says Google Breaches EU Digital Market Rules
May 20, 2025 by
CPI
Latham & Watkins Expands Brussels Antitrust Team
May 20, 2025 by
CPI
Antitrust Mix by CPI
Coordinating Market Actors for the Public Good: Competition Policy as the Industrial Policy of Democratic Economic Governance
May 21, 2025 by
Audrey Stienon & Daniel A. Hanley
State Ownership in Industrial Policy: Assessing Anticompetitive Risks on Mixed Markets
May 21, 2025 by
Jasper P Sluijs
Antitrust Chronicle® – Healthcare Antitrust
May 14, 2025 by
CPI
Healthcare & Antitrust: What to Expect in the New Trump Administration
May 14, 2025 by
Nana Wilberforce, John W O'Toole & Sarah Pugh
Patent Gaming and Disparagement: Commission Fines Teva For Improperly Protecting Its Blockbuster Medicine
May 14, 2025 by
Blaž Višnar, Boris Andrejaš, Apostolos Baltzopoulos, Rieke Kaup, Laura Nistor & Gianluca Vassallo